14-08-2012: In a landmark discovery, researchers from Crucell Holland B.V. and The Scripps Research Institute, announced the identification of the first human monoclonal antibodies that appear capable of disabling all influenza B viruses. The discovery, published in the journal Science, addresses a significant missing link in development of universal therapies and a vaccine. The research was conducted by a team of scientists at Crucell, part of the Janssen Pharmaceutical Companies and Scripps Research, along with collaborators from the Centre of Influenza Research at the University of Hong Kong.
"Despite current vaccines and treatments, influenza remains a major medical problem worldwide. There is a strong need for development of new therapies that go beyond treatment or prevention of infection by single strains, especially with the growing problem of resistance to available anti-viral drugs. A broad-spectrum antibody therapy would be of great benefit for protecting people at high risk of dying from influenza such as senior citizens. The immune system deteriorates with age, so the elderly are not adequately protected by current flu vaccines," says Jaap Goudsmit, director of the Crucell Vaccine Institute and coauthor of the study.
In a landmark discovery, researchers from Crucell Holland B.V. and The Scripps Research Institute, announced the identification of the first human monoclonal antibodies that appear capable of disabling all influenza B viruses. The discovery, published in the journal Science, addresses a sig ... more
Crucell N.V. and The Scripps Research Institute published an article in Science describing Crucell's novel anti-influenza antibody CR8020 and how it neutralizes group 2 influenza A viruses. Attempts to isolate broadly neutralizing antibodies against group 2 viruses have not been previously ... more
Bioceros B.V. announced the extension of the non-exclusive STAR® research license agreement with Crucell. The license agreement with the Netherlands based company Bioceros covers the production of monoclonal antibodies. In addition, the extension of the agreement now includes the right for ... more
Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core ... more
More about Scripps Research Institute
The Scripps Research Institute (TSRI)
10550 North Torrey Pines Road
92037 La Jolla
Six of the world’s translational health research centres announced that they have come together to form a new Global Alliance of Leading Drug Discovery and Development Centres. The aim of this alliance is to strengthen the international academic and/or not-for-profit drug development and co ... more
Scientists from The Scripps Research Institute and Sea Lane Biotechnologies have solved the co-crystal structure of a human antibody that can neutralize influenza viruses in a unique way. The antibody recognizes the crucial structure that flu viruses use to attach to host cells, even though ... more
A fine-tuned combination of two existing pharmaceutical drugs has shown promise as a potential new therapy for people addicted to cocaine — a therapy that would reduce their craving for the drug and blunt their symptoms of withdrawal.In laboratory experiments at The Scripps Research Institu ... more
The Scripps Research Institute, one of the country's largest, private, non-profit research organizations, has always stood at the forefront of basic biomedical science, a vital segment of medical research that seeks to comprehend the most fundamental processes of life. In just three decades ... more